TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Newron Pharmaceuticals SpA ( (CH:NWRN) ) is now available.
Newron Pharmaceuticals announced the approval of its pivotal Phase-III development program ENIGMA-TRS, which includes two studies to evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). The studies, ENIGMA-TRS 1 and ENIGMA-TRS 2, aim to address the unmet medical need for effective treatments in TRS patients by targeting the glutamatergic system, offering a new therapeutic option for those who do not respond adequately to current antipsychotics.
More about Newron Pharmaceuticals SpA
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on developing novel therapies for patients with central and peripheral nervous system disorders. The company is engaged in the development of Evenamide, an innovative treatment for patients with treatment-resistant schizophrenia (TRS) and those with insufficient response to current antipsychotics.
YTD Price Performance: -7.93%
Average Trading Volume: 73,363
Current Market Cap: CHF164.5M
For a thorough assessment of NWRN stock, go to TipRanks’ Stock Analysis page.